LIGAND PHARMACEUTICALS INCORPORATED (LGND) Stock buybacks 2016–2025
LIGAND PHARMACEUTICALS INCORPORATED (LGND) annual stock buyback history — cash paid to repurchase common stock, per SEC filings.
$15.0MFY2025 · since FY2016: $3.9M → $15.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $15.0M | — |
| FY2024 | $0 | — |
| FY2023 | $0 | — |
| FY2022 | $0 | — |
| FY2021 | $0 | -100.0% |
| FY2020 | $78.0M | -82.8% |
| FY2019 | $453.0M | +268.7% |
| FY2018 | $122.9M | +6149.6% |
| FY2017 | $2.0M | -49.6% |
| FY2016 | $3.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More LGND financial trends
LGND RevenueLGND Net incomeLGND Net marginLGND Gross profitLGND Gross marginLGND Operating incomeLGND Operating marginLGND Operating cash flowLGND Free cash flowLGND Capital expendituresLGND Return on equityLGND Dividends paidLGND Total assetsLGND Total liabilitiesLGND Shareholders’ equityLGND overview →